


IN THE CLAIMS:

1. (Currently Amended): A compound of the formula



I

R¹ is hydrogen, (C₀-C₈)alkoxy-(C₁-C₈)alkyl-, wherein the total number of carbon atoms is eight or less, aryl, aryl-(C₁-C₈)alkyl-, heteroaryl, heteroaryl-(C₁-C₈)alkyl-, heterocyclic, heterocyclic-(C₁-C₈)alkyl, (C₃-C₇)cycloalkyl-, or (C₃-C₇)cycloalkyl-(C₁-C₈)alkyl, wherein said aryl and the aryl moiety of said aryl-(C₁-C₈)alkyl- are selected, independently, from phenyl and naphthyl, and wherein said heteroaryl and the heteroaryl moiety of said heteroaryl-(C₁-C₈)alkyl- are selected, independently, from pyrazinyl, benzofuranyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, isoindolyl, benzimidazolyl, purinyl, carbazolyl, 1,2,5-thiadiazolyl, quinazolinyl, pyridazinyl, pyrazinyl, cinnolinyl, phthalazinyl, quinoxalinyl, xanthinyl, hypoxanthinyl, pteridinyl, 5-azacytidinyl, 5-azauracilyl, triazolopyridinyl, imidazolopyridinyl, pyrrolopyrimidinyl, pyrazolopyrimidinyl, oxazolyl, oxadiazoyl, isoxazoyl, thiazolyl, isothiazolyl, furanyl, pyrazolyl, pyrrolyl, tetrazolyl, triazolyl, thienyl, imidazolyl, pyridinyl, and pyrimidinyl; and wherein said heterocyclic and the heterocyclic moiety of said heterocyclic-(C₁-C₈)alkyl- are selected from saturated or unsaturated nonaromatic monocyclic or bicyclic ring systems, wherein said monocyclic ring systems contain from four to seven ring carbon atoms, from one to three of which may optionally be replaced with O, N or S, and wherein said bicyclic ring systems contain from seven to twelve ring carbon atoms, from one to four of which may optionally be replaced with O, N or S; and wherein any of the aryl,

heteroaryl or heterocyclic moieties of R¹ may optionally be substituted with from one to three substituents, preferably with one or two substituents, independently selected from halo (*i.e.*, chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to seven (preferably with from zero to four) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro, (C₁-C₆)alkoxy, (C₁-C₆)alkylamino and [(C₁-C₆)alkyl]₂amino, and wherein any of the alkyl moieties in R¹ (*e.g.*, the alkyl moieties of alkyl, alkoxy or alkylamino groups) ~~may is~~ optionally be substituted with from one to seven (~~preferably with from zero to four~~) fluorine atoms;

R² is ~~hydrogen~~, aryl, heteroaryl, heterocyclic, SO₂R⁴, COR⁴, CONR⁵R⁶, COOR⁴, or C(OH)R⁵R⁶ wherein each of R⁴, R⁵ and R⁶ is defined, independently, as R¹ is defined above, or R⁵ and R⁶, together with the carbon or nitrogen to which they are both attached, form a three to seven membered saturated ring containing from zero to three heterocarbons selected, independently, from O, N and S, and wherein said aryl, heteroaryl, and heterocyclic are defined as such terms are defined above in the definition of R¹, and wherein any of the aryl, heteroaryl and heterocyclic moieties of R² ~~is~~ ~~may~~ optionally be substituted with from one to three substituents, substituents, preferably with one or two substituents, independently selected from halo (*i.e.*, chloro, fluoro, bromo or iodo), (C₁-C₆)alkyl optionally substituted with from one to seven (~~preferably with from zero to four~~) fluorine atoms, phenyl, benzyl, hydroxy, acetyl, amino, cyano, nitro, (C₁-C₆)alkoxy optionally substituted with from one to seven (~~preferably with from zero to four~~) fluorine atoms, (C₁-C₆)alkylamino and [(C₁-C₆)alkyl]₂amino;

R³ is hydroxy, -NHSO₂R⁷, -C(OH)R⁷R⁸, -OC(=O)R⁷, fluorine or -CONHR⁷, wherein R⁷ and R⁸ are the same or different and are selected from hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy and (C₁-C₄)alkoxy-(C₁-C₄)alkyl having a total of four or less carbon atoms, and wherein any of

the alkyl moieties of R^7 and R^8 may optionally be substituted with from one to seven (preferably with from zero to four) fluorine atoms;

Q is oxygen or CH_2 ;

X is CH or N ; and

Z^1 and Z^2 are selected, independently, from hydrogen, halo and (C_1 - C_5)alkyl; with the proviso that there are no two adjacent ring oxygen atoms and no ring oxygen atom adjacent to either a ring nitrogen atom or a ring sulfur atom in any of the heterocyclic or heteroaryl moieties of formula I;

or a pharmaceutically acceptable salt of such compound.

2. (Original): A compound according to claim 1 wherein Q is CH_2 .


3. (Original): A compound according to claim 1 wherein X is CH .

4. (Currently Amended): A compound according to claim 1 wherein X is N .

5. (Original): A compound according to claim 1 wherein Q is oxygen.

6. (Original): A compound according to claim 1 wherein R^3 is OH , $CONH_2$, or fluoro.

7. (Original): A compound according to claim 1 wherein R^2 is selected from $C(OH)(C_2H_6)_2$, $CONCH_3(CH_2CH_3)$, $CON(C_2H_6)_2$ and the following cyclic groups:



8. (Original): A compound according to claim 2 wherein X is CH.

9. (Original): A compound according to claim 2 wherein X is N.

10. (Original): A compound according to claim 6 wherein Q is CH_2 and X is CH.

11. (Original): A compound according to claim 7 wherein Q is CH_2 and X is CH .

12. (Original): A compound according to claim 6 wherein Q is CH_2 and X is N.

13. (Original): A compound according to claim 7 wherein Q is CH_2 and X is N.

14. (Currently Amended): A pharmaceutical composition for treating a disorder or condition

selected from inflammatory diseases such as arthritis, psoriasis, asthma, or inflammatory bowel

disease, disorders of respiratory function such as asthma, cough and apnea, allergies,

gastrointestinal disorders such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and

grafting, urogenital tract disorders ~~such as urinary incontinence~~, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosis, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier.

15. (Cancelled).

16. (Currently Amended): A method for treating a disorder or condition selected from inflammatory diseases ~~such as arthritis, psoriasis, asthma, or inflammatory bowel disease~~, disorders of respiratory function ~~such as asthma, cough and apnea~~, allergies, gastrointestinal disorders ~~such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis~~, stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders ~~such as urinary incontinence~~, chemical dependencies and addictions (e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosis, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, comprising administering to a mammal requiring such treatment

an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

17. (Original): A method for treating a disorder or condition, the treatment of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 that is effective in treating such disorder or condition.

18. (Cancelled).

19. (Currently Amended): A pharmaceutical composition for treating a disorder or condition, the treatment ~~or prevention~~ of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, comprising an opioid receptor binding modulating effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

20. (Currently Amended): A method for treating a disorder or condition selected from inflammatory diseases ~~such as arthritis, psoriasis, asthma, or inflammatory bowel disease,~~ disorders of respiratory function such as asthma, cough and apnea, allergies, gastrointestinal disorders ~~such as gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhoea, functional distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility or secretion, and emesis,~~ stroke, shock, brain edema, head trauma, spinal cord trauma, cerebral ischemia, cerebral deficits subsequent to cardiac bypass surgery and grafting, urogenital tract disorders ~~such as urinary incontinence,~~ chemical dependencies and addictions

(e.g., addictions to or dependencies on alcohol, opiates, benzodiazepines, nicotine, heroin or cocaine), chronic pain, nonsomatic pain, acute pain and neurogenic pain, systemic lupus erythematosis, Hodgkin's disease, Sjogren's disease, epilepsy and rejection in organ transplants and skin grafts in a mammal, comprising administering to a mammal requiring such treatment an opioid receptor binding modulating effective amount of a compound according to claim 1.

21. (Currently Amended): A method for treating a disorder or condition, the treatment ~~or prevention~~ of which can be effected or facilitated by modulating binding to opioid receptors in a mammal, comprising administering to a mammal requiring such treatment an opioid receptor binding modulating effective amount of a compound according to claim 1.

22. (New): A compound according to Claim 1 wherein the alkyl moieties in R¹ is optionally substituted with 1 to 4 fluorine atoms; said aryl, heteroaryl and heterocyclic moieties of R² is optional substituted with one or two substituents and said halo substituents are chloro, fluoro, bromo or iodo; said (C₁-C₆)alkoxy substituent is optionally substituted with one to four fluorine atoms; and said alkyl moieties of R⁷ and R⁸ are optionally substituted with one to four fluorine atoms.

23. (New): A pharmaceutical composition according to Claim 14 wherein said inflammatory diseases comprise asthma, cough and apnea and allergies; said disorders of respiratory function comprise asthma, cough and apnea and allergies; said gastrointestinal disorders comprise gastritis, functional bowel disease, irritable bowel syndrome, functional diarrhea, functional

distension, functional pain, nonulcerogenic dyspepsia and other disorders of motility and secretion and emesis; and said urogenital tract disorders comprise urinary incontinence.

24. (New): A method according to Claim 16 wherein said inflammatory diseases comprise asthma, cough and apnea and allergies; said disorders of respiratory function comprise asthma, cough and apnea and allergies; said gastrointestinal disorders comprise gastritis, functional bowel disease, irritable bowel syndrome, functional pain, nonulcerogenic dyspepsia and other disorders of motility and secretion and emesis; and said urogenital tract disorders comprise urinary incontinence.

25. (New): A method according to Claim 20 wherein said inflammatory diseases comprise arthritis, psoriasis, asthma and inflammatory bowel disease; said disorders of respiratory function comprise asthma, cough and apnea and allergies; said gastrointestinal disorders comprise gastritis, functional bowel disease, irritable bowel syndrome, functional pain, nonulcerogenic dyspepsia and other disorders of motility and secretion and emesis; and said urogenital tract disorders comprise urinary incontinence.